Related Experiment Video
Updated: Jan 18, 2026
In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
Published on: September 29, 2023
The Effect of Lurbinectedin as a Monotherapy and in Combination with Ionizing Radiation on Sarcoma Cell Lines
Hannah Alsheimer1,2, Paula Schiller1,2, Sabine Semrau1,2
1Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Universitätsstraße 27, 91054 Erlangen, Germany.
Background/Objectives:
Soft tissue sarcomas are rare, heterogeneous tumors with limited therapeutic options and suboptimal outcomes in advanced stages. Lurbinectedin is a promising new antineoplastic alkylating agent. This study investigates its cytotoxic effects and its potential as a radiosensitizing agent on soft tissue sarcoma.
Methods:
Four soft tissue sarcoma cell lines were treated with lurbinectedin alone or in combination with ionizing radiation. Single-dose irradiation in a 4-day protocol was compared with prolonged treatment and an additional fractionated ionizing radiation scheme in a 6-day protocol. Cellular responses were analyzed by flow cytometry for apoptosis (Annexin V)/necrosis (7AAD) and cell cycle (Hoechst), clonogenic cell survival, and scratch assays for cell migration.
Results:
In the 4-day protocol, lurbinectedin induced G2/M arrest in all cell lines (p = 0.029) and significantly increased apoptosis/necrosis (p = 0.029) in SW-872. Lurbinectedin-treatment resulted in a decrease (p ≤ 0.002) of clonogenic cells in all cell lines. In the scratch assay, cell migration was delayed in two cell lines (p = 0.048) after lurbinectedin-treatment. Additional radiotherapy had no significant effect compared to lurbinectedin-monotherapy in apoptosis/necrosis and G/2M arrest in the 4-day protocol, clonogenic cell assay, and scratch assay. In the 6-day protocol, lurbinectedin induced an increase (p = 0.029) in G2/M arrest in all cell lines and apoptosis/necrosis in three cell lines, while resulting in a decrease (p < 0.001) of clonogenic cells. Additional radiotherapy had a significant effect on the decrease in clonogenic cells (p ≤ 0.048) in two cell lines but did not increase G2/M arrest and apoptosis/necrosis.
Conclusions:
Lurbinectedin had strong effects on three of the selected cell lines by inducing G2/M arrest, promoting apoptosis/necrosis, and reducing clonogenic survival, suggesting that it may be a promising chemotherapeutic agent in soft tissue sarcoma treatment. The effect on the fourth cell line was limited, as well as the effect on cell migration. Single-dose irradiation occasionally interfered with the effects of Lurbinectedin, whereas adding fractionated irradiation caused an additional decrease in clonogenic survival, indicating that the combination of Lurbinectedin with fractionated ionizing radiation may have promising effects.
Insights
Lurbinectedin effectively targets soft tissue sarcoma cells, inducing cell cycle arrest and apoptosis. Combining lurbinectedin with fractionated radiation enhances its efficacy in reducing cancer cell survival.
Area of Science:
- Oncology
- Pharmacology
Background:
- Soft tissue sarcomas (STS) are rare, heterogeneous cancers with poor outcomes in advanced stages.
- Limited therapeutic options exist for advanced STS.
- Lurbinectedin is an investigational alkylating agent with potential antineoplastic activity.
Purpose of the Study:
- To evaluate the cytotoxic effects of lurbinectedin on STS cell lines.
- To assess lurbinectedin's potential as a radiosensitizer in combination with ionizing radiation.
- To investigate the impact of different radiation fractionation schedules.
Main Methods:
- Four STS cell lines were treated with lurbinectedin alone or combined with ionizing radiation.
- Evaluated cellular responses including apoptosis, necrosis, cell cycle arrest, clonogenic survival, and cell migration.
- Compared single-dose irradiation (4-day protocol) with fractionated irradiation (6-day protocol).
Main Results:
- Lurbinectedin induced G2/M arrest and apoptosis/necrosis in most STS cell lines.
- Lurbinectedin significantly reduced clonogenic cell survival across all tested cell lines.
- Fractionated radiotherapy combined with lurbinectedin showed enhanced reduction in clonogenic survival in two cell lines.
Conclusions:
- Lurbinectedin demonstrates significant cytotoxic effects on STS cells, showing promise as a chemotherapeutic agent.
- The combination of lurbinectedin with fractionated ionizing radiation may offer improved therapeutic outcomes in STS.
- Further investigation is warranted to optimize combination strategies for STS treatment.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...